CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma

Ye,Xiaojing; Wang,Xiaojun; Lu,Rui; Zhang,Jing; Chen,Xinming; Zhou,Gang

doi:10.3892/ol.2018.8520

CD47 as a potential prognostic marker for oral leukoplakia and oral squamous cell carcinoma

Authors:
- Xiaojing Ye
- Xiaojun Wang
- Rui Lu
- Jing Zhang
- Xinming Chen
- Gang Zhou
View Affiliations

Affiliations: The State Key Laboratory Breeding Base of Basic Science of Stomatology (Hubei‑MOST) and Key Laboratory of Oral Biomedicine Ministry of Education, School and Hospital of Stomatology, Wuhan University, Wuhan, Hubei 430079, P.R. China
Published online on: April 17, 2018 https://doi.org/10.3892/ol.2018.8520
Pages: 9075-9080
Copyright: © Ye et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cluster of differentiation (CD)47, which acts as a negative indicator for phagocytic cells, is overexpressed on the surface of multiple human solid tumor cell types. Avoiding phagocytosis by CD47 is required for the progression of solid tumors. The present study investigated the expression of CD47 in oral leukoplakia (OLK) and oral squamous cell carcinoma (OSCC), and preliminarily explored the impact of CD47 on the proliferation of OSCC cells. A total of 56 tissue samples, including 36 cases of OLK, 10 cases of OSCC and 10 cases of normal oral mucosa (NOM) were selected to detect the expression of CD47 by immunohistochemistry. For subgroup analysis, OLK samples were divided into OLK with low‑risk dysplasia (LR‑OLK) and OLK with high‑risk dysplasia (HR‑OLK). The subcellular localization of CD47 was determined by immunofluorescence in three OSCC cell lines (Tca8113, SCC‑9 and Cal‑27). The effect of CD47 antibody on the proliferation of the Cal‑27 cell line was analyzed using the Cell Counting kit‑8 assay. CD47 expression in OLK and OSCC lesions was significantly higher than in NOM (P<0.05). Compared with LR‑OLK, the expression of CD47 in HR‑OLK and OSCC cells was upregulated (P=0.0327 and P=0.0048, respectively). CD47 was highly expressed in OSCC cell lines (Tca8113, Cal‑27 and SCC‑9) and weakly expressed in normal oral keratinocytes. The proliferation of Cal‑27 cells was inhibited by CD47 antibody in a concentration and time‑dependent manner. CD47 may be a reliable biomarker for predicting the progression of oral precancer and cancer, and it may serve as an important molecular target for designing a novel therapy for oral cancer.

View Figures

View References

1	Logan RM: 1st World Congress of the International academy of oral oncology: Oral cancer-a global challenge. Expert Rev Anticancer Ther. 7:975–976. 2007. View Article : Google Scholar : PubMed/NCBI
2	Kulkarni P and Saxena U: Head and neck cancers, the neglected malignancies: Present and future treatment strategies. Expert Opin Ther Targets. 18:351–354. 2014. View Article : Google Scholar : PubMed/NCBI
3	Quan J, Johnson NW, Zhou G, Parsons PG, Boyle GM and Gao J: Potential molecular targets for inhibiting bone invasion by oral squamous cell carcinoma: A review of mechanisms. Cancer Metastasis Rev. 31:209–219. 2012. View Article : Google Scholar : PubMed/NCBI
4	Warnakulasuriya S, Johnson NW and van der Waal I: Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med. 36:575–580. 2007. View Article : Google Scholar : PubMed/NCBI
5	Sarode SC, Sarode GS and Tupkari JV: Oral potentially malignant disorders: Precising the definition. Oral Oncol. 48:759–760. 2012. View Article : Google Scholar : PubMed/NCBI
6	van der Waal I: Potentially malignant disorders of the oral and oropharyngeal mucosa; present concepts of management. Oral Oncol. 46:423–425. 2010. View Article : Google Scholar : PubMed/NCBI
7	Mehrotra R and Gupta DK: Exciting new advances in oral cancer diagnosis: Avenues to early detection. Head Neck Oncol. 3:332011. View Article : Google Scholar : PubMed/NCBI
8	Barclay AN and Van den Berg TK: The interaction between signal regulatory protein alpha (SIRPα) and CD47: Structure, function, and therapeutic target. Annu Rev Immunol. 32:25–50. 2014. View Article : Google Scholar : PubMed/NCBI
9	Jaiswal S, Chao MP, Majeti R and Weissman IL: Macrophages as mediators of tumor immunosurveillance. Trends Immunol. 31:212–219. 2010. View Article : Google Scholar : PubMed/NCBI
10	Takizawa H and Manz MG: Macrophage tolerance: CD47-SIRP-alpha-mediated signals matter. Nat Immunol. 8:1287–1289. 2007. View Article : Google Scholar : PubMed/NCBI
11	Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, et al: The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proc Natl Acad Sci USA. 109:6662–6667. 2012. View Article : Google Scholar : PubMed/NCBI
12	Suzuki S, Yokobori T, Tanaka N, Sakai M, Sano A, Inose T, Sohda M, Nakajima M, Miyazaki T, Kato H and Kuwano H: CD47 expression regulated by the miR-133a tumor suppressor is a novel prognostic marker in esophageal squamous cell carcinoma. Oncol Rep. 28:465–472. 2012. View Article : Google Scholar : PubMed/NCBI
13	Chao MP, Weissman IL and Majeti R: The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. Curr Opin Immunol. 24:225–232. 2012. View Article : Google Scholar : PubMed/NCBI
14	Zhao XW, van Beek EM, Schornagel K, Van der Maaden H, Van Houdt M, Otten MA, Finetti P, Van Egmond M, Matozaki T, Kraal G, et al: CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci USA. 108:18342–18347. 2011. View Article : Google Scholar : PubMed/NCBI
15	Chao MP, Alizadeh AA, Tang C, Jan M, Weissman-Tsukamoto R, Zhao F, Park CY, Weissman IL and Majeti R: Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia. Cancer Res. 71:1374–1384. 2011. View Article : Google Scholar : PubMed/NCBI
16	Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, et al: Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 142:699–713. 2010. View Article : Google Scholar : PubMed/NCBI
17	Chan KS, Espinosa I, Chao M, Wong D, Ailles L, Diehn M, Gill H, Presti J Jr, Chang HY, van de Rijn M, et al: Identification, molecular characterization, clinical prognosis, and therapeutic targeting of human bladder tumor-initiating cells. Proc Natl Acad Sci USA. 106:14016–14021. 2009. View Article : Google Scholar : PubMed/NCBI
18	Warnakulasuriya S, Reibel J, Bouquot J and Dabelsteen E: Oral epithelial dysplasia classification systems: Predictive value, utility, weaknesses and scope for improvement. J Oral Pathol Med. 37:127–133. 2008. View Article : Google Scholar : PubMed/NCBI
19	Lascorz J, Bevier M, Schönfels V W, Kalthoff H, Aselmann H, Beckmann J, Egberts J, Buch S, Becker T, Schreiber S, et al: Association study identifying polymorphisms in CD47 and other extracellular matrix pathway genes as putative prognostic markers for colorectal cancer. Int J Colorectal Dis. 28:173–181. 2013. View Article : Google Scholar : PubMed/NCBI
20	Majeti R, Chao MP, Alizadeh AA, Pang WW, Jaiswal S, Gibbs KD Jr, van Rooijen N and Weissman IL: CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 138:286–299. 2009. View Article : Google Scholar : PubMed/NCBI
21	Jaiswal S, Jamieson CH, Pang WW, Park CY, Chao MP, Majeti R, Traver D, van Rooijen N and Weissman IL: CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis. Cell. 138:271–285. 2009. View Article : Google Scholar : PubMed/NCBI
22	Edris B, Weiskopf K, Volkmer AK, Volkmer JP, Willingham SB, Contreras-Trujillo H, Liu J, Majeti R, West RB, Fletcher JA, et al: Antibody therapy targeting the CD47 protein is effective in a model of aggressive metastatic leiomyosarcoma. Proc Natl Acad Sci USA. 109:6656–6661. 2012. View Article : Google Scholar : PubMed/NCBI
23	Zhu G, He Y, Yang S, Chen B, Zhou M and Xu XJ: Identification of Gene and MicroRNA signatures for oral cancer developed from oral leukoplakia. Biomed Res Int. 2015:8419562015. View Article : Google Scholar : PubMed/NCBI
24	Kim MJ, Lee JC, Lee JJ, Kim S, Lee SG, Park SW, Sung MW and Heo DS: Association of CD47 with natural killer cell-mediated cytotoxicity of head-and-neck squamous cell carcinoma lines. Tumour Biol. 29:28–34. 2008. View Article : Google Scholar : PubMed/NCBI
25	Chao MP, Tang C, Pachynski RK, Chin R, Majeti R and Weissman IL: Extranodal dissemination of non-Hodgkin lymphoma requires CD47 and is inhibited by anti-CD47 antibody therapy. Blood. 118:4890–4901. 2011. View Article : Google Scholar : PubMed/NCBI
26	Fortin G, Raymond M, Van VQ, Rubio M, Gautier P, Sarfati M and Franchimont D: A role for CD47 in the development of experimental colitis mediated by SIRPalpha+CD103-dendritic cells. J Exp Med. 206:1995–2011. 2009. View Article : Google Scholar : PubMed/NCBI
27	Baba N, Van VQ, Wakahara K, Rubio M, Fortin G, Panzini B, Soucy G, Wassef R, Richard C, Tamaz R, et al: CD47 fusion protein targets CD172a+ cells in Crohn's disease and dampens the production of IL-1beta and TNF. J Exp Med. 210:1251–1263. 2013. View Article : Google Scholar : PubMed/NCBI
28	Soto-Pantoja DR, Terabe M, Ghosh A, Ridnour LA, DeGraff WG, Wink DA, Berzofsky JA and Roberts DD: CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 74:6771–6783. 2014. View Article : Google Scholar : PubMed/NCBI
29	Bian Z, Guo Y, Ha B, Zen K and Liu Y: Regulation of the inflammatory response: Enhancing neutrophil infiltration under chronic inflammatory conditions. J Immunol. 188:844–853. 2012. View Article : Google Scholar : PubMed/NCBI
30	Tomizawa T, Kaneko Y, Kaneko Y, Saito Y, Ohnishi H, Okajo J, Okuzawa C, Ishikawa-Sekigami T, Murata Y, Okazawa H, et al: Resistance to experimental autoimmune encephalomyelitis and impaired T cell priming by dendritic cells in Src homology 2 domain-containing protein tyrosine phosphatase substrate-1 mutant mice. J Immunol. 179:869–877. 2007. View Article : Google Scholar : PubMed/NCBI
31	Anderson A and Ishak N: Marked variation in malignant transformation rates of oral leukoplakia. Evid Based Dent. 16:102–103. 2015. View Article : Google Scholar : PubMed/NCBI
32	Öhman J, Mowjood R, Larsson L, Kovacs A, Magnusson B, Kjeller G, Jontell M and Hasseus B: Presence of CD3-positive T-cells in oral premalignant leukoplakia indicates prevention of cancer transformation. Anticancer Res. 35:311–317. 2015.PubMed/NCBI
33	Murata Y, Kotani T, Ohnishi H and Matozaki T: The CD47-SIRPα signalling system: Its physiological roles and therapeutic application. J Biochem. 155:335–344. 2014. View Article : Google Scholar : PubMed/NCBI